最新ニュース Body and Mind (OTC:BMMJ) 株価情報

Body and Mind Inc is a multi-state cannabis operator, which has retail, distribution, cultivation, and/or processing operations in Nevada, California, Arkansas, Ohio and Illinois. It has developed the marquis lifestyle Body and Mind brand in Nevada with penetration into dispensaries and has expanded its brand and products to dispensaries in California. The Body and Mind brand appeals to a wide range of cannabis consumers with products including flowers, oils, extracts (wax, live resin, ambrosia), and edibles. The Company Operates in Three segments; Wholesale, Retail, and All others. The Majority of revenue is derived from the Retail segment.

Body and Mind Inc

Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) will be reporting its fourth-quarter earnings on Tuesday. Wall Street expects 52 cents in EPS and $10.68 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=KO" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is up 7.45% over the past year, 3.74% year-to-date.
Let&#8217;s look at what the charts indicate for Coca-Cola stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/02/43591420/how-to-earn-500-a-month-from-coca-cola-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Coca-Cola Stock Ahead Of Q4 Earnings</a>
<h2 class="wp-block-heading">KO Stock Strongly Bullish Ahead Of Q4 Earnings</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10130007/Screenshot-2025-02-10-at-11.24.24-PM.png" alt="" class="wp-image-775053" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10130007/Screenshot-2025-02-10-at-11.24.24-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10130007/Screenshot-2025-02-10-at-11.24.24-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Coca-Cola stock is exhibiting a strongly bullish trend, with its share price trading above the eight-day, 20-day and 50-day simple moving averages. This sustained buying pressure indicates positive momentum, suggesting the potential for continued upside.
The stock's strength is further reinforced by its Moving Average Convergence Divergence (MACD) indicator at 0.33, signaling bullish momentum.
Additionally, KO stock's Relative Strength Index (RSI) stands at 58.00, placing it in neutral territory but trending toward overbought levels. This suggests that while the stock remains in an uptrend, investors should monitor for potential consolidation or a cooling-off period. 
If buying pressure persists, Coca-Cola stock could continue its bullish trajectory, making it an attractive option for momentum-focused investors.
<h2 class="wp-block-heading">Coca-Cola Analysts See 11% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/KO/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Coca-Cola stock stands at a Buy currently with a price target of $71.30. The latest analyst ratings from RBC Capital, Jefferies and JPMorgan imply an 11.3% upside for KO stock, with an average price target of $71.33.
Stock Price Action: Coca-Cola stock was trading at $64 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43494592/jpmorgan-picks-winners-losers-after-deepseek-debut-how-alphabet-amazon-intel-and-oracle-rank">JPMorgan Picks Winners, Losers After DeepSeek Debut: How Alphabet, Amazon, Intel And Oracle Rank</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Trading Ideas

Coca-Cola Stock Is Bubbling Higher: Can Q4 Earnings Keep The Fizz Going?

A new <a href="https://www.researchsquare.com/article/rs-5921911/v1">study</a> suggests that cannabinoids like THC, CBD and CBN may help regulate blood sugar levels, potentially outperforming some existing diabetes drugs. It should be noted, however, that since this study is not peer-reviewed and remains purely theoretical, any potential applications remain speculative at this stage. The research requires further validation before any clinical applications can be considered.
<h3 class="wp-block-heading">Study Highlights Multi-Target Potential Of Cannabinoids</h3>
Researchers from the University of the Free State and the University of Yaoundé 1 conducted an in silico molecular docking study to assess the interactions between six cannabinoids and four key enzymes involved in glucose metabolism: dipeptidyl peptidase-4 (DPP-4), α-glucosidase, α-amylase and invertase. These enzymes play essential roles in breaking down carbohydrates and regulating post-meal glucose spikes, making them primary targets for type 2 diabetes treatments.
According to the study, cannabinoids showed stronger binding affinities to these enzymes compared to some standard diabetes drugs, with the exception of DPP-4 inhibitors. THC and CBN demonstrated particularly strong interactions, suggesting they might modulate multiple metabolic pathways simultaneously.
The study suggests that cannabinoids exhibit multi-target binding to key type 2 diabetes drug targets, indicating their potential for further investigation as anti-diabetic agents.
<h3 class="wp-block-heading">Why This Matters</h3>
With <a href="https://diabetesatlas.org/atlas/tenth-edition/">537 million</a> people worldwide living with diabetes, the demand for effective and safer treatment options continues to grow. While traditional diabetes medications focus on single pathways, cannabinoids may offer a multi-target approach, potentially improving glucose control while reducing side effects.
Previous studies have hinted at cannabis compounds&#8217; metabolic effects, with research showing that <a href="https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1150189/full">CBD</a> may reduce insulin resistance and inflammation, while <a href="https://pubmed.ncbi.nlm.nih.gov/33526143/">THCV</a> has been linked to appetite suppression and improved metabolic function. However, the exact mechanisms remain unclear.
<h3 class="wp-block-heading">The Caveats: What This Study Doesn&#8217;t Prove</h3>
Despite the promising results, this study remains theoretical. It relies solely on computer simulations, meaning no clinical trials or real-world testing have been conducted to confirm the effects of cannabinoids on blood sugar regulation.
Additionally, while the study suggests that cannabinoids bind well to key enzymes, binding affinity alone does not guarantee therapeutic efficacy. Factors such as bioavailability, metabolism and dosage need to be studied in laboratory and human trials before any conclusions can be drawn.
It's also important to note that the research has not yet been peer-reviewed, meaning it has not undergone rigorous scientific scrutiny. Until further studies validate these findings, cannabinoids should not be considered a proven treatment for diabetes. While these findings are interesting, they do not constitute medical proof. Without clinical validation, there is no certainty that cannabinoids will have the same effects in living organisms as seen in computer models.
<h3 class="wp-block-heading">What's Next?</h3>
For cannabinoids to be seriously considered in diabetes management, animal and human trials must confirm their efficacy and safety. Future research should also explore how different cannabinoids interact with each other and whether non-psychoactive compounds like CBG and THCV could offer metabolic benefits without the high association with THC.
While cannabis-based medicines are already being explored for conditions like epilepsy and chronic pain, their potential in diabetes remains largely untapped. If future studies support these findings, we may see the development of novel cannabinoid-based therapies targeting blood sugar control.
For now, this study is a stepping stone, not a breakthrough—a signal that further investigation is warranted, but not a replacement for existing treatments.
Lead image via Shutterstock

Cannabis

News

Health Care

Could Cannabis Compounds Outperform Diabetes Drugs? Early Findings Show Potential, But More Research Is Needed

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 150 points on Monday.
The Dow traded up 0.40% to 44,482.54 while the NASDAQ gained 1.16% to 19,750.22. The S&amp;P 500 also rose, gaining, 0.75% to 6,071.29.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a>
Leading and Lagging Sectors Energy shares surged by 2% on Monday.
In trading on Monday, financial shares fell by 0.6%.
Top Headline
U.S. consumer inflation expectations for the year ahead came in steady for a third straight month at 3% in January.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SpringWorks Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) shares shot up 36% to $54.85 after announcing Merck KGaA is in advanced discussions to acquire the company.</li>
<li>Shares of Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>)got a boost, surging 42% to $5.78 after the company announced it received FDA fast-track designation for eRapa.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) shares were also up, gaining 28% to $331.46 after the company reported better-than-expected fourth-quarter financial results and first-quarter revenue outlook.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares dropped 59% to $3.1893. On Friday, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and stiffening of the lung tissue.</li>
<li>Shares of Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) were down 11% to $179.24. The company announced its president and CEO Eddie Capel will retire.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) was down, falling 31% to $37.60 after Needham cut its price target on the stock from $74 to $54.</li>
</ul>
Commodities In commodity news, oil traded up 1.7% to $72.22 while gold traded up 1.7% at $2,935.20.
Silver traded up 0.2% to $32.515 on Monday, while copper rose 2.6% to $4.7060.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.58%, Germany's DAX 40 rose 0.57% and France's CAC 40 rose 0.52%. Spain's IBEX 35 Index rose 0.16%, while London's FTSE 100 rose 0.77%.
Asia Pacific Markets
Asian markets closed mostly higher on Monday, with Japan's Nikkei 225 gaining 0.04%, China's Shanghai Composite Index climbing 0.56%, Hong Kong's Hang Seng Index gaining 1.84% and India's BSE Sensex falling 0.70%.
Economics
U.S. consumer inflation expectations for the year ahead came in steady for a third straight month at 3% in January.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Markets

BDRX

MANH

MNDY

PLRX

SMTC

SWTX

Crude Oil Rises Sharply; Manhattan Associates Shares Slide

U.S. stocks settled lower on Friday, with the Dow Jones index dipping more than 400 points as investors digested the jobs report for January. Wall Street also recorded losses last week as renewed fears over inflation and trade tariffs eroded risk appetite.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 89%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) and raised the price target from $135 to $180 on Feb. 7. This analyst sees around 4% upside in the stock.</li>
<li>Recent News: On Feb. 6, Cloudflare reported quarterly earnings of 19 cents per share, which beat the analyst consensus estimate of 18 cents.</li>
</ul>
Analyst: Alexander Paris
<ul>
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 88%</li>
<li>Latest Rating: Maintained an Outperform rating on H&amp;R Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) with a price target of $70 on Feb. 5. This analyst sees a 32% surge in the stock.</li>
<li>Recent News: On Feb. 4, H&amp;R Block reported worse-than-expected second-quarter financial results.</li>
</ul>
Analyst: Mark Kelley 
<ul>
<li>Analyst Firm: Stifel</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and increased the price target from $245 to $275 on Feb. 7. This analyst sees around 18% upside in the stock.</li>
<li>Recent News: On Feb. 6, Amazon.com reported fourth-quarter net sales of $187.8 billion, up 10% year-over-year. The net sales beat a Street consensus estimate of $187.3 billion according to data from Benzinga Pro.</li>
</ul>
Analyst: Josh Sullivan
<ul>
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) and raised the price target from $4 to $7 on Feb. 5. This analyst sees around 8% surge in the stock.</li>
<li>Recent News: On Jan. 28, the company's subsidiary Planet Labs Germany GmbH inked a multi-year agreement with the European Space Agency (ESA).</li>
</ul>
Analyst: John Todaro
<ul>
<li>Analyst Firm: Needham</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Coinbase Global, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and cut the price target from $420 to $330 on Feb. 7. This analyst sees around 18% upside in the stock.</li>
<li>Recent News: On Jan. 19, Coinbase announced the addition of Chris LaCivita, President Donald Trump&#8217;s co-campaign manager in 2024, to its Global Advisory Council.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Price Target

Analyst Ratings

AMZN

COIN

This Analyst With 86% Accuracy Rate Sees More Than 18% Upside In Amazon.com, - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 12% bullish and 50%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $288,604, and 2 are calls, for a total amount of $143,091.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $17.0 for Teva Pharmaceutical Indus during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale trades within a strike price range from $15.0 to $17.0 in the last 30 days. 
<h3>Teva Pharmaceutical Indus 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214939_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$15.00</td>
<td>$91.2K</td>
<td>1.2K</td>
<td>301</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.16</td>
<td>$2.06</td>
<td>$2.16</td>
<td>$17.00</td>
<td>$76.8K</td>
<td>10.7K</td>
<td>611</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.28</td>
<td>$1.07</td>
<td>$1.28</td>
<td>$15.00</td>
<td>$74.2K</td>
<td>2.4K</td>
<td>592</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.52</td>
<td>$0.4</td>
<td>$0.51</td>
<td>$16.50</td>
<td>$51.8K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.45</td>
<td>$1.38</td>
<td>$1.42</td>
<td>$17.00</td>
<td>$35.5K</td>
<td>15.3K</td>
<td>250</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
In light of the recent options history for Teva Pharmaceutical Indus, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Teva Pharmaceutical Indus Standing Right Now?</h3>
<ul>
<li>With a volume of 4,482,422, the price of TEVA is down -0.68% at $16.71. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 86 days.</li>
</ul>
<h3>Expert Opinions on Teva Pharmaceutical Indus</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $28.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Teva Pharmaceutical Indus, targeting a price of $27. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $30. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $26. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Teva Pharmaceutical Indus, which currently sits at a price target of $30. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Teva Pharmaceutical Indus options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

TEVA

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bullish move on FTAI Aviation. Our analysis of options history for FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) revealed 18 unusual trades.
Delving into the details, we found 61% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $406,128, and 8 were calls, valued at $3,388,990.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $130.0 for FTAI Aviation over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for FTAI Aviation options trades today is 1262.7 with a total volume of 7,525.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for FTAI Aviation's big money trades within a strike price range of $85.0 to $130.0 over the last 30 days.
<h3>FTAI Aviation Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214934_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTAI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$34.6</td>
<td>$33.0</td>
<td>$33.1</td>
<td>$90.00</td>
<td>$3.1M</td>
<td>1.0K</td>
<td align="right">951</td>
</tr>
<tr>
<td>FTAI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$14.5</td>
<td>$13.8</td>
<td>$13.8</td>
<td>$108.00</td>
<td>$56.5K</td>
<td>140</td>
<td align="right">100</td>
</tr>
<tr>
<td>FTAI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$100.00</td>
<td>$55.0K</td>
<td>179</td>
<td align="right">501</td>
</tr>
<tr>
<td>FTAI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.0</td>
<td>$5.2</td>
<td>$5.5</td>
<td>$100.00</td>
<td>$55.0K</td>
<td>179</td>
<td align="right">301</td>
</tr>
<tr>
<td>FTAI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.0</td>
<td>$5.2</td>
<td>$5.5</td>
<td>$100.00</td>
<td>$55.0K</td>
<td>179</td>
<td align="right">201</td>
</tr>
</tbody>
</table>

<h3>About FTAI Aviation</h3>
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate strong and stable cash flows with the potential for earnings growth and asset appreciation.
Following our analysis of the options activities associated with FTAI Aviation, we pivot to a closer look at the company's own performance.
<h3>Where Is FTAI Aviation Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,047,297, the price of FTAI is up by 5.45%, reaching $118.99.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 16 days from now.</li>
</ul>
<h3>What Analysts Are Saying About FTAI Aviation</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $130.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel persists with their Buy rating on FTAI Aviation, maintaining a target price of $100. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $160. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest FTAI Aviation options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

FTAI

FTAI Aviation Options Trading: A Deep Dive into Market Sentiment

Whales with a lot of money to spend have taken a noticeably bullish stance on SpringWorks Therapeutics.
Looking at options history for SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) we detected 68 trades.
If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 32% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $125,618 and 65, calls, for a total amount of $3,475,358.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $60.0 for SpringWorks Therapeutics over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for SpringWorks Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across SpringWorks Therapeutics's significant trades, within a strike price range of $25.0 to $60.0, over the past month.
<h3>SpringWorks Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214929_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$12.8</td>
<td>$11.2</td>
<td>$12.0</td>
<td>$45.00</td>
<td>$270.0K</td>
<td>4.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$30.00</td>
<td>$203.7K</td>
<td>308</td>
<td>144</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$13.4</td>
<td>$12.5</td>
<td>$13.4</td>
<td>$40.00</td>
<td>$116.5K</td>
<td>3.9K</td>
<td>732</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$27.1</td>
<td>$24.3</td>
<td>$26.0</td>
<td>$30.00</td>
<td>$104.0K</td>
<td>308</td>
<td>204</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$16.5</td>
<td>$14.7</td>
<td>$15.5</td>
<td>$40.00</td>
<td>$97.6K</td>
<td>3.9K</td>
<td>910</td>
</tr>
</tbody>
</table>

<h3>About SpringWorks Therapeutics</h3>
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
<h3>Where Is SpringWorks Therapeutics Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 10,783,844, the SWTX's price is up by 37.09%, now at $55.22. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 10 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for SpringWorks Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In SWTX Options

Vice President J.D. Vance is being put in charge of overseeing a deal to save TikTok after President Donald Trump changed his mind and decided to temporarily save the <a href="https://www.benzinga.com/general/social-media/25/01/43088960/trump-suspends-us-tiktok-ban-for-75-days-with-executive-order-but-legal-and-market-uncertainty-looms-over-platforms-future">Chinese social media app.</a>
What Happened: Vance, who is a <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39799850/5-things-you-might-not-know-about-j-d-vance-hillbilly-elegy-author-bitcoin-holder-first-mi">former venture capitalist</a>, is being tasked with helping land the best deal for the potential sale of TikTok's U.S. division to a buyer in the United States.
Vance and National Security Adviser Michael Waltz have been put in charge of the task, according to a Punchbowl <a href="https://punchbowl.news/article/tech/vance-waltz-tiktok-portfolio/">report</a>.
Sources say Vance is in charge of "quarterbacking a deal to save TikTok," which comes after Trump gave 75 days for TikTok parent ByteDance to work out a deal that would give the U.S. or an American company ownership of the U.S. TikTok division.
In 2024, Congress passed a bipartisan law banning TikTok, a decision later upheld by the U.S. Supreme Court. However, Trump's executive order delayed enforcement, leaving TikTok's future uncertain as ByteDance races to find a buyer and finalize a deal.
ByteDance temporarily shut off access to TikTok to hundreds of millions of Americans before reversing course after Trump's executive order. Smartphone owners in the U.S. who did not have TikTok previously installed are unable to download it during the current waiting period.
Vance and Waltz face challenges to make a deal that appeases several parties, including Trump, ByteDance, China, members of Congress, the Senate Intelligence Committee and the potential buying group.
As a former member of Congress and venture capitalist, Vance&#8217;s deal-making experience in both politics and investments could help broker an agreement. This move may also serve as an early test of his effectiveness in the vice-presidential role.
Trump previously suggested that the American government could own part of TikTok, potentially through the newly created U.S. sovereign wealth fund.
The president has voiced support for Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) co-founder Larry Ellison or Tesla CEO Elon Musk <a href="https://www.benzinga.com/general/social-media/25/01/43181940/elon-musk-or-larry-ellison-dan-ives-on-who-could-win-tiktoks-billion-dollar-soap-opera-someone-hand-picked-from-beijing-but-also-trumps-white-house">buying TikTok. </a>Musk recently said he is not interested. Billionaire Frank McCourt, Shark Tank member Kevin O'Leary and content creator MrBeast are <a href="https://www.benzinga.com/25/01/43325891/backed-by-youtube-king-mrbeast-group-of-american-investors-including-roblox-ceo-lock-in-over-20-billion-for-tiktok-takeover-but-they-have-not-heard-back-directly-from-bytedance">among the names </a>that have expressed interest in buying TikTok.
Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) are also names that pop up with potential interest in acquiring a stake in TikTok, <a href="https://www.wsj.com/tech/trump-vance-tiktok-deal-0e3b8bc1">according </a>to The Wall Street Journal.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="http://•	https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021025">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="http://•	https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021025"><img loading="lazy" decoding="async" width="1024" height="331" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-1024x331.png" alt="" class="wp-image-775138" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-1024x331.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2-1536x497.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10140321/gov-trades2.png 1890w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Why It's Important: Vance's task of finding the right deal for all parties involved faces tough odds.
TikTok CEO Shou Chew met with White House officials last week and pitched a U.S. joint venture that would be headquartered in the United States with a board of directors made up of a majority of U.S. members, with the country also overseeing data security.
ByteDance has not been open to selling TikTok off in its entirety. The discussion of a TikTok deal also comes as Trump's tariff proposals and talks with China over trade could make the ByteDance-owned app a leverage piece in a potential trade war.
Vance was a former principal at Peter Thiel's Mithril Capital in 2016 and 2017. He later left Mithril to work at Revolution LLC in 2017, an investment firm founded by AOL founder Steve Case.
In 2019, Vance co-founded Narya Capital, a venture capital fund that received backing from Thiel, Eric Schmidt and Marc Andreessen.
With his venture capital history, Vance has experience in the technology sector and connections to several notable venture capitalists.
While Vance worked for several VC firms,<a href="https://www.benzinga.com/general/politics/24/07/39916075/j-d-vance-venture-capital-background-under-scrutiny-it-never-seemed-like-he-was-even-working-it-"> his work ethic</a> has been questioned by several former co-workers.
&#8220;It never seemed like he was even working,&#8221; a former coworker&nbsp;<a href="https://www.businessinsider.com/jd-vance-venture-capitalist-colleagues-2024-7" target="_blank" rel="noreferrer noopener">told&nbsp;</a>Business Insider. &#8220;It felt like his full-time job was the book.&#8221;
Former coworkers said Vance did not close a single deal a year after he started with the firm.
Vance has acknowledged his potential lack of contribution at Mithril.
&#8220;How useful I&#8217;ve been on that front is probably debatable,&#8221; Vance said in a previous interview on his venture capital history.
For Vance, securing a deal for TikTok could help win him praise from Trump and Congress members and silence the naysayers who doubt his VC deal-making abilities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42654769/tiktok-ban-under-trump-president-elect-wants-to-keep-months-after-pelosi-said-follow-the-money">TikTok Ban Under Trump? President-Elect Reconsiders As Pelosi Says &#8216;Follow The Money&#8217;</a></li>
</ul>
Photo: Shutterstock

Politics

Global

MSFT

ORCL

JD Vance 'Quarterbacking' TikTok Deal: Will His Venture Capital Experience Secure A Win?

HIV-Treatment-focused giant&nbsp;Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is scheduled to report fourth-quarter and full-year 2024 results on February 11, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43286943/gilead-sciences-to-release-fourth-quarter-full-year-2024-financial-results-on-tuesday-february-11-" rel="noreferrer noopener">after the market close</a>.
Analysts estimate fourth-quarter adjusted EPS of $1.70 and revenues of $7.14 billion. The Wall Street forecasts fiscal year 2024 adjusted EPS of $4.41 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $28.31 billion</a>.
Gilead reported third-quarter adjusted EPS of $2.02, down from $2.29 a year ago, beating the consensus of $1.55.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39435880/gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatmen" rel="noreferrer noopener">Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments</a>
The HIV drug maker reported third-quarter sales of $7.55 billion, up 7% year over year, beating the consensus of $7 billion, primarily due to higher sales in HIV and Veklury&nbsp;(remdesivir), Oncology, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost" rel="noreferrer noopener">and Liver Disease</a>.
Gilead will report the first full quarter sales from Livdelzi&nbsp;(seladelpar) after gaining FDA accelerated approval in mid-August 2024 for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal" rel="noreferrer noopener">primary biliary cholangitis</a>.
In October, Gilead Sciences&nbsp;announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41409405/after-failed-confirmatory-trial-gilead-withdraws-us-accelerated-approval-of-trodelvy-as-bladder-c" rel="noreferrer noopener">1 (PD-L1) inhibitor</a>.
In January, Gilead Sciences&nbsp;and&nbsp;LEO Pharma&nbsp;announced a strategic partnership to accelerate the development and commercialization of LEO Pharma&#8217;s small molecule oral STAT6 for inflammatory diseases.
Gilead will acquire LEO Pharma&#8217;s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders.
Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead the development of potential topical formulations of STAT6 inhibitors.
LEO Pharma can receive up to $1.7 billion, including an upfront payment of $250 million.
In addition, LEO Pharma may also receive tiered royalties ranging from the high single-digits to the mid-teens on sales of oral STAT6 products.
The transaction with LEO Pharma is expected to reduce Gilead&#8217;s GAAP and non-GAAP 2025 EPS by <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42932896/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-pro" rel="noreferrer noopener">approximately $0.15 &#8211; $0.17</a>.
Price Action: GILD stock is down 0.78% at $95.29&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43597062/incyte-records-15-jump-in-2024-sales-on-strong-jakafi-opzelura-sales-says-2025-to-be-catalyst-rich-including-four-launches" target="_blank" rel="noreferrer noopener">Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Large Cap

Guidance

General

GILD

What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?

WIIM

REAL

RealReal shares are trading lower after the company announced a $183 million debt exchange and provided Q4, FY25, FY26, and Q1 revenue guidance.

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $222.86, a high estimate of $240.00, and a low estimate of $210.00. This upward trend is apparent, with the current average reflecting a 5.93% increase from the previous average price target of $210.38.
<img src="https://www.benzinga.com/files/images/story/2025/1739214054_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Guidewire Software's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$210.00</td>
<td>-</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$228.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Aaron Kimson</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$231.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$231.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Guidewire Software. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Guidewire Software compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Guidewire Software's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Guidewire Software's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GWRE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Guidewire Software analyst ratings.</a>
<h2>Delving into Guidewire Software's Background</h2>
Guidewire Software provides software solutions for property and casualty insurers. Flagship product InsuranceSuite is an on-premises system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a cloud-based offering, as well as a variety of other add-on applications.
<h3>A Deep Dive into Guidewire Software's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Guidewire Software's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 26.76%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Guidewire Software's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.48%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Guidewire Software's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.7%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Guidewire Software's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.38%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Guidewire Software's debt-to-equity ratio surpasses industry norms, standing at 0.78. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GWRE

The Analyst Verdict: Guidewire Software In The Eyes Of 14 Experts

Ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.4, a high estimate of $61.00, and a low estimate of $40.00. Witnessing a positive shift, the current average has risen by 4.46% from the previous average price target of $48.25.
<img src="https://www.benzinga.com/files/images/story/2025/1739214046_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for AtriCure's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into AtriCure's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AtriCure analyst ratings.</a>
<h2>About AtriCure</h2>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
<h3>A Deep Dive into AtriCure's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining AtriCure's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.93% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AtriCure's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.69% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AtriCure's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.3%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AtriCure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.17.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRC

Expert Outlook: AtriCure Through The Eyes Of 5 Analysts

During the last three months, 5 analysts shared their evaluations of Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Winnebago Industries, revealing an average target of $59.2, a high estimate of $70.00, and a low estimate of $54.00. This current average represents a 3.35% decrease from the previous average price target of $61.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739214034_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Winnebago Industries by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Brett Andress</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Brandon Rolle</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Albanese</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Winnebago Industries. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Winnebago Industries compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Winnebago Industries's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Winnebago Industries's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WGO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Winnebago Industries analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Winnebago Industries</h2>
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was nearly $3 billion in fiscal 2024. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 83% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total RV unit volume was 38,796 in fiscal 2024. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
<h3>Winnebago Industries: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Winnebago Industries's revenue growth over 3 months faced difficulties. As of 30 November, 2024, the company experienced a decline of approximately -18.01%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Winnebago Industries's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.83% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Winnebago Industries's ROE excels beyond industry benchmarks, reaching -0.41%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Winnebago Industries's ROA excels beyond industry benchmarks, reaching -0.22%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.6, Winnebago Industries adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Winnebago Industries Stock

Investors with a lot of money to spend have taken a bullish stance on Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MBLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Mobileye Global.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 40%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $978,868, and 7 are calls, for a total amount of $382,941.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $16.0 to $30.0 for Mobileye Global over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Mobileye Global's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Mobileye Global's substantial trades, within a strike price spectrum from $16.0 to $30.0 over the preceding 30 days.
<h3>Mobileye Global Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214031_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.5</td>
<td>$8.55</td>
<td>$10.5</td>
<td>$25.00</td>
<td>$840.0K</td>
<td>907</td>
<td align="right">800</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.06</td>
<td>$18.00</td>
<td>$184.2K</td>
<td>23.1K</td>
<td align="right">726</td>
</tr>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$4.55</td>
<td>$4.4</td>
<td>$4.45</td>
<td>$20.00</td>
<td>$102.8K</td>
<td>2.8K</td>
<td align="right">232</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$2.49</td>
<td>$2.21</td>
<td>$2.34</td>
<td>$30.00</td>
<td>$46.3K</td>
<td>2.9K</td>
<td align="right">217</td>
</tr>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.4</td>
<td>$7.15</td>
<td>$7.21</td>
<td>$20.00</td>
<td>$36.0K</td>
<td>164</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Mobileye Global</h3>
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. Mobileye is the Company's only reportable operating segment. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System &amp; Vehicles. It also provides data services to Expedite Maintenance Operations with AI-Powered Road Survey Technology.
In light of the recent options history for Mobileye Global, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Mobileye Global</h3>
<ul>
<li>Trading volume stands at 10,496,245, with MBLY's price up by 15.06%, positioned at $18.49.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 73 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mobileye Global</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Mobileye Global, maintaining a target price of $18. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Mobileye Global, targeting a price of $17. 
&#x2A; Reflecting concerns, an analyst from Oppenheimer lowers its rating to Outperform with a new price target of $28. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Mobileye Global, maintaining a target price of $22. 
&#x2A; In a positive move, an analyst from B of A Securities has upgraded their rating to Neutral and adjusted the price target to $19. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Mobileye Global with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

MBLY

This Is What Whales Are Betting On Mobileye Global

Across the recent three months, 37 analysts have shared their insights on Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">10</td>
<td align="right">18</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $107.16, a high estimate of $135.00, and a low estimate of $78.00. This upward trend is evident, with the current average reflecting a 13.3% increase from the previous average price target of $94.58.
<img src="https://www.benzinga.com/files/images/story/2025/1739214026_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Fortinet's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Dan Bergstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$115.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$115.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$112.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$101.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$114.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$103.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Underperform</td>
<td>$78.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$110.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Shaul Eyal</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Dan Bergstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$97.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fortinet. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Fortinet compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Fortinet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Fortinet's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FTNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fortinet analyst ratings.</a>
<h2>About Fortinet</h2>
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 700,000 customers across the world.
<h3>Financial Insights: Fortinet</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Fortinet displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 13.0%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Fortinet's net margin excels beyond industry benchmarks, reaching 35.8%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Fortinet's ROE stands out, surpassing industry averages. With an impressive ROE of 90.26%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Fortinet's ROA excels beyond industry benchmarks, reaching 6.39%. This signifies efficient management of assets and strong financial health.
Debt Management: Fortinet's debt-to-equity ratio is below the industry average at 1.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTNT

Fortinet Stock: A Deep Dive Into Analyst Perspectives (37 Ratings)

Deep-pocketed investors have adopted a bullish approach towards Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WMT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 31 extraordinary options activities for Walmart. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 38% bearish. Among these notable options, 15 are puts, totaling $950,673, and 16 are calls, amounting to $1,239,887.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $115.0 for Walmart over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Walmart options trades today is 1941.6 with a total volume of 14,556.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Walmart's big money trades within a strike price range of $80.0 to $115.0 over the last 30 days.
<h3>Walmart 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214025_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$9.95</td>
<td>$9.9</td>
<td>$9.95</td>
<td>$97.50</td>
<td>$299.5K</td>
<td>1.3K</td>
<td>301</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$0.66</td>
<td>$0.63</td>
<td>$0.63</td>
<td>$93.00</td>
<td>$267.7K</td>
<td>251</td>
<td>5.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$24.25</td>
<td>$23.05</td>
<td>$24.1</td>
<td>$80.00</td>
<td>$241.0K</td>
<td>499</td>
<td>100</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$8.6</td>
<td>$8.55</td>
<td>$8.6</td>
<td>$100.00</td>
<td>$146.2K</td>
<td>2.4K</td>
<td>173</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$0.68</td>
<td>$0.64</td>
<td>$0.64</td>
<td>$93.00</td>
<td>$84.0K</td>
<td>251</td>
<td>1.3K</td>
</tr>
</tbody>
</table>

<h3>About Walmart</h3>
Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.
Following our analysis of the options activities associated with Walmart, we pivot to a closer look at the company's own performance.
<h3>Current Position of Walmart</h3>
<ul>
<li>Trading volume stands at 7,398,452, with WMT's price up by 1.08%, positioned at $102.24.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 10 days.</li>
</ul>
<h3>Professional Analyst Ratings for Walmart</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $109.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Walmart, maintaining a target price of $110. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $105. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Walmart, targeting a price of $112. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Walmart, maintaining a target price of $108. 
&#x2A; An analyst from UBS persists with their Buy rating on Walmart, maintaining a target price of $113. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Walmart with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Walmart's Latest Options Trends

Financial giants have made a conspicuous bearish move on Lam Research. Our analysis of options history for Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) revealed 25 unusual trades.
Delving into the details, we found 24% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $273,151, and 20 were calls, valued at $2,552,444.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $100.0 for Lam Research, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Lam Research's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Lam Research's whale activity within a strike price range from $70.0 to $100.0 in the last 30 days. 
<h3>Lam Research Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214020_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$15.4</td>
<td>$15.35</td>
<td>$15.35</td>
<td>$70.00</td>
<td>$765.9K</td>
<td>602</td>
<td align="right">500</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.75</td>
<td>$13.7</td>
<td>$13.75</td>
<td>$75.00</td>
<td>$618.9K</td>
<td>1.5K</td>
<td align="right">451</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$9.5</td>
<td>$9.35</td>
<td>$9.35</td>
<td>$86.00</td>
<td>$240.2K</td>
<td>121</td>
<td align="right">258</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$14.6</td>
<td>$14.45</td>
<td>$14.45</td>
<td>$100.00</td>
<td>$144.5K</td>
<td>964</td>
<td align="right">100</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$13.2</td>
<td>$13.05</td>
<td>$13.05</td>
<td>$75.00</td>
<td>$126.5K</td>
<td>1.1K</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Lam Research</h3>
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
In light of the recent options history for Lam Research, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Lam Research</h3>
<ul>
<li>With a volume of 4,427,834, the price of LRCX is up 1.34% at $83.43. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 72 days.</li>
</ul>
<h3>What The Experts Say On Lam Research</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $89.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Cantor Fitzgerald upgrades its rating to Overweight with a revised price target of $100. 
&#x2A; Showing optimism, an analyst from Keybanc upgrades its rating to Overweight with a revised price target of $95. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Lam Research, maintaining a target price of $75. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Lam Research with a target price of $85. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $90. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Lam Research, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

LRCX

Spotlight on Lam Research: Analyzing the Surge in Options Activity

Throughout the last three months, 7 analysts have evaluated Equitable Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Equitable Hldgs and provided 12-month price targets. The average target is $59.0, accompanied by a high estimate of $70.00 and a low estimate of $53.00. This current average has increased by 13.46% from the previous average price target of $52.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739214018_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Equitable Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Cave Montazeri</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Equitable Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Equitable Hldgs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Equitable Hldgs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Equitable Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EQH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Equitable Hldgs analyst ratings.</a>
<h2>Discovering Equitable Hldgs: A Closer Look</h2>
Equitable Holdings Inc is a financial services company in the U.S. The company provides variable annuities, tax-deferred investment and retirement plans, employee benefits, and protection solutions for individuals, families, and small businesses. Its business segments include Individual Retirement, Group Retirement, Investment Management and Research, Protection Solutions, Wealth Management, and Legacy. The Individual Retirement segment offers annuity products, the Group Retirement segment provides tax-deferred investment and retirement services, the Investment Management and Research segment consists of diversified investment management, research, and related services, and the Protection Solutions segment focuses on life insurance products.
<h3>Financial Milestones: Equitable Hldgs's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Equitable Hldgs's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -15.12% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Equitable Hldgs's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -4.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Equitable Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -17.01%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Equitable Hldgs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.05%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Equitable Hldgs's debt-to-equity ratio surpasses industry norms, standing at 3.36. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Equitable Hldgs's Future

4 analysts have shared their evaluations of Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.5, along with a high estimate of $20.00 and a low estimate of $19.00. This current average reflects an increase of 4.45% from the previous average price target of $18.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1739214012_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Arcutis Biotherapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Arcutis Biotherapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Arcutis Biotherapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Arcutis Biotherapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Arcutis Biotherapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARQT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arcutis Biotherapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Arcutis Biotherapeutics's Background</h2>
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
<h3>Arcutis Biotherapeutics's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Arcutis Biotherapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.44% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Arcutis Biotherapeutics's net margin excels beyond industry benchmarks, reaching -92.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Arcutis Biotherapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -24.21%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Arcutis Biotherapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.42%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 1.33, Arcutis Biotherapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARQT

4 Analysts Have This To Say About Arcutis Biotherapeutics

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Mizuho cut General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) price target from $72 to $65. Mizuho analyst John Baumgartner maintained a Neutral rating. General Mills shares closed at $58.82 on Friday. See how other analysts view this stock.</li>
<li>Piper Sandler raised the price target for monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from $345 to $385. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. monday.com shares closed at $258.24 on Friday. See how other analysts view this stock.</li>
<li>Mizuho slashed WEX Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) price target from $215 to $170. Mizuho analyst Dan Dolev maintained an Outperform rating. WEX shares closed at $152.08 on Friday. See how other analysts view this stock.</li>
<li>Stifel cut the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $492 to $474. Stifel analyst Stephen Gengaro maintained a Buy rating. Tesla shares closed at $361.62 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised the price target for Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) from $8 to $10. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating. Yum! Brands shares closed at $144.01 on Thursday. See how other analysts view this stock.</li>
<li>Scotiabank slashed Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) price target from $150 to $140. Scotiabank analyst Patrick Colville maintained a Sector Perform rating. Qualys shares settled at $8.37 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital cut Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) price target from $9.5 to $9. RBC Capital analyst Nik Modi maintained a Sector Perform rating. Newell Brands shares closed at $7.13 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Macquarie raised PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) price target from $115 to $117. Macquarie analyst Paul Golding maintained an Outperform rating. PayPal shares closed at $77.31 on Friday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James raised the price target for Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) from $200 to $250. Raymond James analyst Josh Beck maintained a Strong Buy rating. Reddit shares settled at $224.23 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group slashed Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) price target from $11 to $10. Evercore ISI Group analyst Chris McNally maintained an In-Line rating. Ford shares closed at $9.24 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

PTON

PYPL

RDDT

TSLA

Tesla To $474? Here Are 10 Top Analyst Forecasts For Monday

Body and Mind announces debt financing

Body & Mind (TSE:BAMM) has released an update. Body and Mind Inc. has entered into a credit facility agreement with Bengal Catalyst Fund for up to ...

Body and Mind Secures $2.3 Million Credit Facility

Cannabis operator Body and Mind reports delay in filing annual financial statements

Body & Mind (TSE:BAMM) has released an update. Body and Mind Inc., a cannabis company, is nearing completion of its delayed annual financial filing...

Body and Mind Nears Completion of Financial Filings

An announcement from Body & Mind ( ($TSE:BAMM) ) is now available. Body and Mind Inc. announced the upcoming opening of a new dispensary in Lynwood...

Body and Mind Announces New Dispensary and Nevada Divestment

The latest update is out from Body & Mind ( ($TSE:BAMM) ). Body and Mind Inc. has provided an update on the delayed filing of its 2024 annual finan...

Body and Mind Inc. Nears Completion of 2024 Financial Filings

The latest update is out from Body & Mind ( ($TSE:BAMM) ). Body and Mind Inc. announced a cease trade order issued by the British Columbia Securiti...

Body and Mind Faces Cease Trade Order and Director Resignation

Body and Mind announces sale of Illinois assets

Body & Mind ( ($TSE:BAMM) ) has provided an announcement. Body and Mind Inc. has announced the sale of its Illinois assets, NMG IL 1 and NMG IL 4, to

Body and Mind Inc. Sells Illinois Assets to Dutchess Cannabis

Body & Mind ( ($TSE:BAMM) ) has provided an update. Body and Mind Inc. announced a need to restate its financial statements for certain periods in ...

Comments

Body and Mind

ニュース

最新ニュース Body and Mind (OTC:BMMJ) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル